Multiple myeloma (MM) is the second most common hematologic malignancy and remains
incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs) …

Despite therapeutic advances over the past decades, multiple myeloma (MM) remains a
largely incurable disease with poor prognosis in high-risk patients, and thus new treatment …

CD19 Chimeric antigen receptor (CAR) T cell therapy has been shown to be effective for B
cell leukemia and lymphoma. Many researchers are now trying to develop CAR T cells for …

Multiple myeloma remains an incurable disease for most patients despite the advent of
novel therapies. Advances in the field of adoptive immunotherapy using chimeric antigen …

Overview A dvances in targeted therapies, including immunoomodulators, proteasome
inhibitors, monoclonal antibodies, histone deaetylase inhibitors, and chimeric antigen …

Meta-analysis and systematic review of plerixafor for stem cell mobilization for autologous stem
cell transplant (ASCT) All content on this site is intended for healthcare professionals only. By …

Substantial evolution in cancer therapy has been witnessed lately, steering mainly towards
immunotherapeutic approaches, replacing or in combination with classical therapies …

Les progres thérapeutiques récents, tels que le développement des agents
immunomodulateurs, des inhibiteurs du protéasome ou des anticorps monoclonaux, ont …